Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets in adolescents

Matsuoka, Tomokazu; Bernstein, David I.; Masuyama, Keisuke; Nolte, Hendrik; Okamiya, Kazuhiro; Seitzberg, Dorthe; Nelson, Harold S.

doi:10.1111/pai.12747

Cited by 19 publications

(20 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In two large mixed adult and pediatric trials, the use of HDM SLIT tablets was effective in reducing rhinitis symptoms after a year of administration, with improvements also seen in medication use and quality of life . Pooled data on adolescents from these trials showed that treatment with HDM SLIT tablets resulted in a 22% decrease in rhinitis symptoms and that it was safe and well tolerated . However, the aqueous formulation of HDM extract has very limited evidence of benefit, with the majority of pediatric studies failing to find improvement in symptom/ medication scores .…”

Section: What Is the Evidence For Ait In The Treatment Of Allergic mentioning

confidence: 99%

Allergen Immunotherapy in Children User’s Guide

Alvaro‐Lozano

Akdiş

Alviani

et al. 2020

Pediatric Allergy Immunology

190

237

View full text Add to dashboard Cite

Aim and scopePediatric Allergy and Immunology publishes original contributions and comprehensive reviews related to the understanding and treatment of immune defi ciency, allergic infl ammatory and infectious diseases in children. Other areas of interest include development of specifi c and accessory immunity, and the immunological interaction during pregnancy and lactation between mother and child. As the journal is intended to promote communication between scientists engaged in basic research and clinicians working with children, both clinical and experimental work will be published.

show abstract

Section: What Is the Evidence For Ait In The Treatment Of Allergic mentioning

confidence: 99%

Allergen Immunotherapy in Children User’s Guide

Alvaro‐Lozano

Akdiş

Alviani

et al. 2020

Pediatric Allergy Immunology

190

237

View full text Add to dashboard Cite

show abstract

“…En el cuadro 5.2 se indican rangos para las dosis de mantenimiento probablemente efectivas en ITSL, en relación con las dosis recomendadas para ITSC. [63][64][65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80] 5.5. Fase de mantenimiento: cómo comparar la dosis diaria de ITSL con la dosis mensual de ITSC La guía EAACI-RA y la alemana indican que los metaanálisis han mostrado heterogeneidad considerable en el nivel de eficacia entre los diferentes productos y las diferentes dosis para ITSL.…”

Section: Dosis De La Itsl Según Guías Madre Y Estudios Originales Refunclassified

GUIMIT 2019, Guía Mexicana de Inmunoterapia. Guía de diagnóstico de alergia mediada por IgE e inmunoterapia aplicando el método ADAPTE

Larenas‐Linnemann¹,

Luna-Pech²,

Rodríguez-Pérez³

et al. 2019

RAM

View full text Add to dashboard Cite

Antecedentes: En México, la inmunoterapia con alérgenos (ITA) y con veneno de himenópteros (VIT) se practica tradicionalmente combinando criterios de las escuelas europea y estadounidense; los dos tipos de extractos están comercialmente disponibles en México. Para una ITA adecuada es crucial un diagnóstico oportuno.Objetivo: Presentar GUIMIT 2019, Guía Mexicana de Inmunoterapia 2019, de base amplia, actualizada, que abarca temas de diagnóstico, indicaciones, dosificación, mecanismos, efectos adversos de la ITA y expectativas con esta modalidad de tratamiento.Método: Con la participación de múltiples grupos mexicanos de alergólogos, que incluían los centros formadores universitarios en alergia e inmunología, se desarrolló el documento de la guía según la metodología ADAPTE. Las guías de inmunoterapia de la European Academy of Allergy and Clinical Immunology, The American Academy of Allergy, Asthma and Immunology, German Society for Allergology and Clinical Immunology y del American College of Allergy, Asthma, and Immunology se seleccionaron como guías fuente, ya que recibieron la puntuación AGREE-II más alta entre las guías internacionales disponibles; su evidencia conforma la base científica de GUIMIT 2019.Resultados: En GUIMIT 2019 se emiten recomendaciones fuertes o débiles (sugerencias) acerca de temas directamente relacionados con el diagnóstico in vivo o in vitro de las enfermedades alérgicas mediadas por IgE, la preparación y aplicación de ITA o VIT y sus efectos adversos; se incluye la revisión de las modalidades de ITA para el futuro. Todos los argumentos que se exponen fueron discutidos y votados con > 80 % de aprobación.Conclusión: Un grupo amplio y diverso de expertos en ITA y VIT emitió recomendaciones transculturizadas basadas en evidencia, que alcanzaron consenso; con ellas se pretende mejorar y homologar la práctica de la inmunoterapia en México.

show abstract

“…Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations was questioned in a systematic review [ 64 ]. Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets were studied in adolescents [ 65 ].…”

Section: Immunotherapymentioning

confidence: 99%

Highlights and recent developments in airway diseases in EAACI journals (2017)

Bousquet

Akdiş²,

Grattan

et al. 2018

Clin Transl Allergy

View full text Add to dashboard Cite

The European Academy of Allergy and Clinical Immunology (EAACI) owns three journals: Allergy, Pediatric Allergy and Immunology and Clinical and Translational Allergy. One of the major goals of EAACI is to support health promotion in which prevention of allergy and asthma plays a critical role and to disseminate the knowledge of allergy to all stakeholders including the EAACI junior members. There was substantial progress in 2017 in the identification of basic mechanisms of allergic and respiratory disease and the translation of these mechanisms into clinics. Better understanding of molecular and cellular mechanisms, efforts for the development of biomarkers for disease prediction, novel prevention and intervention studies, elucidation of mechanisms of multimorbidies, entrance of new drugs in the clinics as well as recently completed phase three clinical studies and publication of a large number of allergen immunotherapy studies and metaanalyses have been the highlights of the last year.

show abstract

Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets in adolescents

Abstract: Background: House dust mite (HDM) respiratory allergy is a common and burdensome

Cited by 19 publications

References 24 publications

Allergen Immunotherapy in Children User’s Guide

Allergen Immunotherapy in Children User’s Guide

GUIMIT 2019, Guía Mexicana de Inmunoterapia. Guía de diagnóstico de alergia mediada por IgE e inmunoterapia aplicando el método ADAPTE

Highlights and recent developments in airway diseases in EAACI journals (2017)

Contact Info

Product

Resources

About